Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $715.56 million. Operations ...

CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028.

CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational ...

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $715.56 million. Operations: CureVac ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...